Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 175-182

  Miyahara, T ^a,b   Mochinaga, S ^a   Kimura, S ^c   Aragane, N ^c   Yakabe, T ^d   Morita, S ^e   Okudaira, K ^b   Fujito, H ^a  

^a SAGA UNIVERSITY HOSPITAL   (Japan)

^b Saga Prefectural Hospital Koseikan   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d SAGA UNIVERSITY   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Actual body weight; Cancer; Chemotherapy; Ideal body weight; Obesity

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LEVOLEUCOVORIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; RETROSPECTIVE STUDIES;

EID: 84872308598     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1994-8     Document Type: Article

References (25)

1. Kelly T, Yang W, Chen CS, Reynolds K, He J (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32:1431-1437
2. Tang H, Dong X, Hassan M, Abbruzzese JL, Li D (2011) Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 20:779-792
3. Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, Shariat SF (2011) Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol 186:66-72
4. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71-87
5. Blouin RA, Warren GW (1999) Pharmacokinetic considerations in obesity. J Pharm Sci 88:1-7
6. Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW (1994) Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 55:392-398
7. Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621-625
8. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327
9. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219-222
10. Abdah-Bortnyak R, Tsalic M, Haim N (2003) Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability. Med Oncol 20:363-368
11. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB 3rd, Fuchs CS (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22:648-657
12. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA (2009) Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 35:69-78
13. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14:3000-3008
14. Colleoni M, Li S, Gelbefr RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A (2005) Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108-1110
15. American Society of Clinical Oncology (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: american Society of Clinical Oncology clinical practice guideline. J Clin Oncol 13:1553-1561
16. Japan Society for the Study of Obesity (2002) New criteria for 'Obesity Disease' in Japan. Circ J 66:987-992
17. Du Bois D, Du Bois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arc Intern Med 17:863-871
18. Matsuzawa Y, Tokunaga K, Kotani K, Keno Y, Kobayashi T, Tarui S (1990) Simple estimation of ideal body weight from body mass index with the lowest morbidity. Diabetes Res Clin Pract 10:159-164
19. Calle E, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348:1625-1638
20. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307:491-497
21. Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91:2246-2257
22. Munakata M, Nunokawa T, Yoshinaga K, Toyota T; J-TOPP Study Group (2006) Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension-a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 29:515-521
23. Superfin D, Iannucci AA, Davies AM (2007) Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist 12:1070-1083
24. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713
25. Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL (2007) Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 25:2063-2069